AGA Center for Diagnostics & Therapeutics
Drug development is a complex, time-consuming and expensive process requiring the cooperation of various stakeholders. To help facilitate this process, the AGA Center for Diagnostics and Therapeutics provides objective, independent guidance to companies, regulators, investors and health-care professionals on the development of new therapies and diagnostic tests for digestive disorders.
Expertise and Opportunities
• Identification of Experts and Organization of Expert Meetings
• Clinical Study Design and Endpoint Development
• Development of Educational Programs and Resources
We invite AGA partners to suggest other issues facing the drug and diagnostic industries related to clinical development and regulatory approval.
Read GI & Hepatology News’ coverage of the 2016 AGA Drug Development Conference, which focused on new and emerging drugs for the treatment of GERD, gastroparesis, EoE and dyspepsia.
FDA Comment Letter
The AGA Center for Diagnostics and Therapeutics submitted comments on FDA’s 2015 draft guidance document entitled “Gastroparesis: Clinical Evaluation of Drugs for Treatment.”
Introduction to the Center
Learn more about why the center was established and its work in the drug and diagnostic space in this AGA Perspectives editorial by Dr. Colin Howden.
GERD Treatment Overview
Dr. Colin Howden, chair of the center, discusses the highs and lows of drug development for gastroesophageal reflux disease in a blog post on Applied Clinical Trials.
Functional Dyspepsia Trial Design
In this blog post, center board member Dr. Nimish Vakil discusses the need for improved definitions and clinical trials to develop treatment for this common condition.
Since inflammatory bowel disease (IBD) is linked to disruption of the intestinal microbiome, antibiotics have come under increasing scrutiny as possible environmental catalysts in IBD – especially if taken in early childhood. So far, the association has been...read more
Primary care providers can successfully manage direct-acting antiviral (DAA) treatment for hepatitis C, though some complicated cases should still be referred to specialists, experts say. Recent studies have shows that hepatitis C treatment by primary care physicians...read more
2017-07-20 12:59:31 UTC AGA members: Find this interesting? Share your thoughts with colleagues in AGA Community. July 20, 2017 The Crohn’s & Colitis Congress™, combines the strengths of the nation’s leading IBD patient organization,...read more
Scientific Advisory Board
Colin W. Howden, MD, AGAF, Chair
University of Tennessee Health Science Center, Memphis
Tara A. Altepeter, MD, FDA Liaison*
Food and Drug Administration, Silver Spring, MD
J. Summer Bell III, MD, AGAF
Gastroenterology Ltd., Virginia Beach, VA
Glenn T. Furuta, MD
Children’s Hospital Colorado, Aurora
M. Scott Harris, MD, AGAF
Avaxia Biologics and Georgetown University, Washington, DC
Rajeev Jain, MD, AGAF, Governing Board Liaison
Texas Digestive Disease Consultants, Dallas
Loren Laine, MD, AGAF
Yale University School of Medicine, Fairfield, CT
Gary R. Lichtenstein, MD, AGAF
University of Pennsylvania, Philadelphia
Fred Poordad, MD
University of Texas Health Science Center, San Antonio
Debra G. Silberg, MD, PhD
Shire Pharmaceuticals, Wayne, PA
Nimish B. Vakil, MD, AGAF
University of Wisconsin Medical School, Summit, WI
Teresa L. Wright, MD, AGAF
Genentech, San Francisco, CA
*Denotes non-voting member.
Are you ready to take the next step?
To learn more about the center, please contact Alison Kim, senior director of research and innovation.